Please Wait.....
Report
McKesson Corporation (MCK : NYSE) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI's, and Recent Trends
Company Report I 2024-10-29 I 126 Pages I Quaintel Research
Report Summary
McKesson Corporation (MCK : NYSE) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI's, and Recent Trends Report is a comprehensive and easily accessible overview of McKesson Corporation's business operations. It provides a detailed analysis of the company's financial and strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.
The report begins with in-depth information about McKesson Corporation including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.
Next, the report assesses McKesson Corporation's strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. The PESTLE analysis evaluates the external factors impacting the company's operations and market environment. Additionally, By integrating these strategic analyses, the report offers a comprehensive understanding of McKesson Corporation's overall strategic standing and supports informed decision-making and strategic planning.
The report also covers McKesson Corporation's financial analysis basis of latest income statement, balance sheet, and cash flow statement. Key financial ratios related to profitability, asset turnover, credit, market, and long-term solvency are outlined, providing guidance for investment decisions. Furthermore, the report compares McKesson Corporation's financial parameters with those of its competitors, offering a unique analysis of the competitive landscape. This information helps manage the business environment and improve sales activities by gaining insight into competitors' operations.
Finally, the report includes recent news and deal activities undertaken by McKesson Corporation enhancing awareness of the company's business trends, growth perspectives, and more.
Key Highlights
McKesson Corporation, founded in 1833, is one of the oldest healthcare industry. It operates as a diversified healthcare services and information technology company that plays a vital role in improving healthcare outcomes around the world. McKesson provides pharmaceutical distribution, medical supplies, healthcare management software, and biopharmaceutical services, making it a pivotal player in healthcare logistics and technology solutions.
With a rich history spanning over 190 years, McKesson continues to be a cornerstone in global healthcare, addressing the needs of patients, healthcare providers, and pharmaceutical companies through its robust distribution networks and technology platforms.
McKesson Corporation in the News:-
- 09-Oct-2024 - InspiroGene by McKesson Unveils First-of-its-Kind Report on State of the Cell and Gene Therapy Landscape, Revealing Unparalleled Optimism Amidst Complex Challenges
- 01-Oct-2024 - McKesson Launches InspiroGene, a Dedicated Business to Guide and Support the Commercialization of Cell and Gene Therapies
- 25-Sep-2024 - VORANIGO (vorasidenib), FDA Approved for the Treatment of Patients with IDH-mutant Diffuse Glioma, Available at Biologics by McKesson
- 10-Sep-2024 - ZOKINVY (lonafarnib), the only FDA Approved Treatment for Hutchinson-Gilford Progeria Syndrome, Now Exclusively Available at Biologics by McKesson
- 09-Sep-2024 - RYTELOTM (imetelstat), FDA Approved for Treatment of Patients with Low- to Intermediate-1 Risk Myelodysplastic Syndromes (MDS) with Transfusion-dependent Anemia, Available at Biologics by McKesson
Scope
- Tactical Analysis:- Various strategic frameworks to gain insights into a company's competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
- Business Strategy:- Contributes to shaping the company's overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
- Financial Position:- Provide valuable information on the financial performance and investor sentiment surrounding the company. Indicating the level of confidence and expectations in the company's future prospects. These components collectively contribute to understanding the financial health and market perception of the company.
- Company Fundamentals:- These fundamentals offer valuable insights into the company's history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
- Competitive Landscape:- An identification of the company's main competitors, providing insights into the competitive landscape it operates in.
Reasons to Buy
- Comprehensive Understanding of the McKesson Corporation's internal and external factors through SWOT analysis, PESTLE analysis, Financial Analysis, and Competitors Benchmarking.
- Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
- Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
- Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
- Financial Performance Evaluation provides crucial insights into key financial ratios and trends, supporting better financial decision-making and resource allocation.
- Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.
Additionally, available deep-dive analysis on the company McKesson Corporation:
- McKesson Corporation Value Chain Analysis
- McKesson Corporation Porter's Five Forces Analysis
- McKesson Corporation VRIO Analysis
- McKesson Corporation BCG Analysis
- McKesson Corporation Segmentation, Targeting and Positioning (STP) Analysis
- McKesson Corporation Ansoff Matrix Analysis
Table of Contents
COMPANY EXECUTIVE SUMMARY 1
Table of Contents 2
Tables 7
Charts 8
McKesson Corporation - Key Company Facts 9
McKesson Corporation - Company Description 10
McKesson Corporation - Top Executives 11
McKesson Corporation- Top Executives Biographies 12
McKesson Corporation- Head Office & Locations 14
Head Office - Country 14
Key Subsidiaries 15
Key Joint Ventures 16
McKesson Corporation - Products and Services 17
Products 17
Services 18
McKesson Corporation - Historic Events 20
McKesson Corporation - Company's Management Discussion 22
McKesson Corporation - Company's Mission and Vision 24
Mission 24
Vision 24
McKesson Corporation - Corporate Strategy 25
McKesson Corporation - Business Description 27
U.S. Pharmaceutical Segment 28
Prescription Technology Solutions (RxTS) Segment 29
Medical-Surgical Solutions Segment 29
International Segment 30
McKesson Corporation - ESG Spotlight 31
Environment 31
Social 32
Corporate Governance 32
McKesson Corporation - SWOT Analysis 33
Overview 33
Strengths 35
Weaknesses 39
Opportunities 42
Threats 45
McKesson Corporation - PESTLE Analysis 47
Overview 47
Political Factors 49
Economic Factors 51
Social Factors 53
Technological Factors 55
Legal Factors 57
Environmental Factors 59
McKesson Corporation - Financial Deep Dive 60
Share Price Trend - Oct-2023 to Oct-2024 (Average Share Closing Price) 60
Profit and Loss Statement 62
Summary of Profit and Loss Statement 62
Balance Sheet 64
Summary of Balance Sheet 64
Cash Flow Statement 66
Summary of Cash Flow Statement 66
Key Financial Ratio Analysis 68
McKesson Corporation - Ratio Charts 69
Activity Ratio Charts 69
Growth Ratios Charts 70
Leverage Ratio Charts 71
Liquidity Ratio Charts 72
Profitability Ratio Charts 73
Competing Players 74
Snapshot of Competing Players 75
Cencora Inc 75
Key Company Facts 75
Company Description 75
Snapshot of Competing Players 78
Cardinal Health Inc 78
Key Company Facts 78
Company Description 78
Snapshot of Competing Players 80
Johnson & Johnson Services, Inc. 80
Key Company Facts 80
Company Description 80
Snapshot of Competing Players 82
Medtronic plc 82
Key Company Facts 82
Company Description 82
Snapshot of Competing Players 84
Stryker Corporation 84
Key Company Facts 84
Company Description 84
McKesson Corporation - In the News 86
09-Oct-2024- InspiroGene by McKesson Unveils First-of-its-Kind Report on State of the Cell and Gene Therapy Landscape, Revealing Unparalleled Optimism Amidst Complex Challenges 86
01-Oct-2024- McKesson Launches InspiroGene, a Dedicated Business to Guide and Support the Commercialization of Cell and Gene Therapies 88
25-Sep-2024- VORANIGO (vorasidenib), FDA Approved for the Treatment of Patients with IDH-mutant Diffuse Glioma, Available at Biologics by McKesson 89
10-Sep-2024- ZOKINVY (lonafarnib), the only FDA Approved Treatment for Hutchinson-Gilford Progeria Syndrome, Now Exclusively Available at Biologics by McKesson 90
09-Sep-2024- RYTELOTM (imetelstat), FDA Approved for Treatment of Patients with Low- to Intermediate-1 Risk Myelodysplastic Syndromes (MDS) with Transfusion-dependent Anemia, Available at Biologics by McKesson 91
05-Sep-2024- McKesson Corporation Announces Sale of Rexall and Well.ca Businesses to Birch Hill Equity Partners 92
03-Sep-2024- The US Oncology Network Extends its Reach in Illinois as Illinois CancerCare Joins The Network 93
02-Jul-2024- McKesson Releases Fiscal Year 2024 Impact Report 95
26-Jun-2024- McKesson Corporation Announces First Quarter Fiscal 2025 Earnings Release Date 95
26-Jun-2024- McKesson ideaShare Ignites and Inspires Independent Community Pharmacies 95
19-Jun-2024- CAMCEVI (leuprolide) 42mg injection emulsion, FDA Approved for Treatment of Advanced Prostate Cancer, Available Exclusively at Biologics by McKesson 98
03-Jun-2024- McKesson's Board of Directors Elects Deborah Dunsire as New Director 99
03-Jun-2024- Real-World Research Presented at ASCO 2024 Indicates Clinical Trial Participation by Older Adults with Cancer Does Not Affect Emergency Room Visits or Hospice Enrollment 100
20-Dec-2023- FABHALTA (iptacopan), FDA Approved for the Treatment of Adults with Paroxysmal Nocturnal Hemoglobinuria, Available at Biologics by McKesson 101
16-Aug-2023- Genpact Extends Relationship to Transform McKesson's Finance Operations for Enhanced Service and Competitive Growth 101
10-Jul-2023- Cancer center of kansas joins the us oncology network 103
22-Jun-2023- Mckesson unveils new private brand of over-the-counter pharmacy products 104
05-Jun-2023- Research presented at asco 2023 shows implementing value-based care strategies such as dose rounding reduces drug waste and total cost of care 105
05-Apr-2023- Biologics by mckesson named the exclusive pharmacy for fda- approved skyclarys (omaveloxolone) for the treatment of friedreich's ataxia 106
17-Jan-2023- The us oncology network continues its rapid growth into new communities, adding epic care and nexus health 107
22-Dec-2022- Fyarro (sirolimus protein-bound particles for injectable suspension) (albumin-bound), fda approved for treatment of locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor 109
McKesson Corporation- Key Deals 110
17-Oct-2024 - Ontada Collaborates with Microsoft to Transform Unstructured Oncology Data with Azure OpenAI Technology 110
26-Aug-2024 - McKesson Signs Agreement to Acquire Controlling Interest in Florida Cancer Specialists & Research Institute's Core Ventures 112
19-Sep-2022 - Mckesson signs agreement to acquire rx savings solutions 114
09-May-2022 - Oncohealth secures strategic investments from arsenal capital partners & mckesson corporation 116
Appendix 118
Definitions 118
SWOT Analysis 118
PESTLE Analysis 118
Value Chain Analysis 118
ESG Spotlight 118
Financial Deep Dive 118
Financial Ratios - 119
Activity Ratios 119
Growth Ratios 120
Leverage Ratios 121
Liquidity Ratios 122
Market Ratios 123
Profitability Ratios 123
Research Methodology 124
Disclaimer 125
Contact Us 125
Tables
Table 1: McKesson Corporation - Company Facts 9
Table 2: McKesson Corporation - Top Executives 11
Table 3: McKesson Corporation - Top Executives Biographies 12
Table 4: McKesson Corporation - Subsidiaries 15
Table 5: McKesson Corporation - Key Joint Ventures 16
Table 6: McKesson Corporation - Products 17
Table 7: McKesson Corporation - Services 18
Table 8: McKesson Corporation - Historic Events 20
Table 9: McKesson Corporation - Share Price Trend - Oct-2023 to Oct-2024 60
Table 10: McKesson Corporation- Ratio Analysis - 2021-2024 68
Table 11: McKesson Corporation -Competing Players 74
Charts
Figure 1: McKesson Corporation- SWOT Analysis 34
Figure 2: McKesson Corporation - PESTLE Analysis 48
Figure 3: McKesson Corporation - Average Share Price Trend - Oct-2023 to Oct-2024 61
Figure 4: McKesson Corporation - Profit and Loss Statement - 2021-2024 63
Figure 5: McKesson Corporation - Balance Sheet - 2021-2024 65
Figure 6: McKesson Corporation - Cash Flow Statement 2021-2024 67
Figure 7: McKesson Corporation - Activity Ratio Charts 69
Figure 8: McKesson Corporation - Growth Ratio Charts (Value %) 70
Figure 9: McKesson Corporation - Leverage Ratio Charts 71
Figure 10: McKesson Corporation - Liquidity Ratio Charts 72
Figure 11: McKesson Corporation - Profitability Ratio Charts (Value %) 73
Figure 12: Competing Players - Cencora Inc - Key Financials 77
Figure 13: Competing Players - Cardinal Health Inc - Key Financials 79
Figure 14: Competing Players - Johnson & Johnson Services, Inc. - Key Financials 81
Figure 15: Competing Players - Medtronic plc - Key Financials 83
Figure 16: Competing Players - Stryker Corporation - Key Financials 85
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security